0000000000393670

AUTHOR

M. Barve

showing 3 related works from this author

Updated results of the PARP1/2 inhibitor pamiparib in combination with low-dose (ld) temozolomide (TMZ) in patients (pts) with locally advanced or me…

2019

Oncologymedicine.medical_specialtyTemozolomideSurrogate endpointbusiness.industryCancerHematologyNeutropeniamedicine.diseaseChemotherapy regimenPoly (ADP-Ribose) Polymerase Inhibitorchemistry.chemical_compoundOncologychemistryResponse Evaluation Criteria in Solid TumorsInternal medicinemedicineRucaparibbusinessmedicine.drugAnnals of Oncology
researchProduct

530MO Clinical benefit in biomarker-positive patients (pts) with locally advanced or metastatic solid tumours treated with the PARP1/2 inhibitor pami…

2020

Oncologymedicine.medical_specialtyTemozolomidebusiness.industryLow doseLocally advancedHematologyPARP1OncologyInternal medicinemedicineBiomarker (medicine)businessmedicine.drugAnnals of Oncology
researchProduct

Preliminary results from a phase I study of GBR 1302, a bispecific antibody T-cell engager, in HER2 positive cancers

2018

0301 basic medicineBispecific antibodybusiness.industryT cellCancerPhases of clinical researchHematologymedicine.diseasePhase i study03 medical and health sciences030104 developmental biology0302 clinical medicinemedicine.anatomical_structureOncology030220 oncology & carcinogenesismedicineCancer researchbusinessAnnals of Oncology
researchProduct